ITOS   $7.67  -1.67% Market Closed After Close 7.66 -0.13%

Iteos Therapeutics Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Trend changed from down and flat to linear down.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-03 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-08-03 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-08-03 Signal in MACD changed from bullish recovery to bullish. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: signal line crossed the middle level.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 25.00
Mean unverified/preliminary 25.00 / 25.00
Target Price Low / High 16.00 / 47.00
Median / STD DEV 21.50 / 11.19
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi ActivelyBuy Sell ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy Sell ActivelyBuy
ma50 None None None
ma100 Buy Buy Buy
Candlestick PatternJan. 14, 2025 Three Stars -
ISIN US46565G1040
ceo Dr. Michel Detheux Ph.D.
Website https://www.iteostherapeutics.com
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.